Transition Therapeutics launches public offering of common stock

Cowen is bookrunner for fundraising to advance drug candidates

By Marisa Wong

Madison, Wis., Feb. 11 – Transition Therapeutics Inc. announced that it has begun an underwritten public offering of its common shares.

Cowen and Co., LLC is the bookrunner, and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC and LifeSci Capital LLC are the co-managers.

The company expects to use proceeds from the stock offering for general corporate purposes, including expenditures related to the advancement of its drug candidates through the various clinical trial phases.

Transition is a biopharmaceutical development company based in Toronto.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.